ASX:ANP

ANTISENSE THERAPEUTICS LIMITED

4W AVG VOLUME

758.7k

Data provided by Weblink | as of close 2020-01-24

4W AVG TURNOVER

$61.48k

ANTISENSE THERAPEUTICS LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise

< $50k

Investors Interested in Next Raise

< 10

How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

2. View Terms

View the full term sheet for the capital raise.

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

10 March 2019

Placement

Raised

$1.6m

Offer Price

$0.033

Discount

-

Price at Close

-

Market Cap

-

Re-listed

12-03-2019

Company Overview

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Type

Listed Company

GICS Sub-industry

Pharmaceuticals

Head Office

6 Wallace Ave, Toorak VIC 3142, Australia

Website

www.antisense.com.au

Pharmaceuticals

Health Care

Biotech

Biotech & Health

Price Chart

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.